References
- Rossouw JE, Anderson GL, Prentice RL, . Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002;288:321–33
- Panay N, Studd J. Progestogen intolerance and compliance with hormone replacement therapy in menopausal women. Hum Reprod Update 1997;3:159–71
- Casper RF, Chapdelaine A. Estrogen and interrupted progestin: a new concept for menopausal hormone replacement therapy. Am J Obstet Gynecol 1993;168:1188–94
- Kroft J, Klostermann NR, Moody JR, . A novel regimen of combination transdermal estrogen and intermittent vaginally administered progesterone for relief of menopausal symptoms. Gynecol Endocrinol 2010;26:902–8
- Cano A, Tarín JJ, Dueñas JL. Two-year prospective, randomized trial comparing an innovative twice-a-week progestin regimen with a continuous combined regimen as postmenopausal hormone therapy. Fertil Steril 1999;71:129–36
- The Writing Group for the PEPI Trial. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1996;275:370–5
- Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat 2008;107:103–11
- L’hermite M, Simoncini T, Fuller S, . Could transdermal estradiol + progesterone be a safer postmenopausal HRT? A review. Maturitas 2008;60:185–201
- Cicinelli E. Intravaginal oestrogen and progestin administration: advantages and disadvantages. Best Pract Res Clin Obstet Gynaecol 2008;22:391–405
- Birkhäuser MH, Reinecke I. Current trends in hormone replacement therapy: perceptions and usage. Climacteric 2008;11:192–200
- Kurman RJ, Norris HJ. Endometrial hyperplasia and related cellular changes. In Kurman RJ, ed. Blaustein's Pathology of the Female Genital Tract, 4th edn. New York, NY: Springer Verlag, 1994:411–37
- Sitruk-Ware R. Pharmacological profile of progestins. Maturitas 2008;61:151–7
- Hermsmeyer RK, Thompson TL, Pohost GM, . Cardiovascular effects of medroxyprogesterone acetate and progesterone: a case of mistaken identity? Nat Clin Pract Cardiovasc Med 2008;5:387–95
- Bakken K, Fournier A, Lund E, . Menopausal hormone therapy and breast cancer risk: impact of different treatments. The European Prospective Investigation into Cancer and Nutrition. Int J Cancer 2011;128:144–56
- Moyer DL, de Lignieres B, Driguez P, . Prevention of endometrial hyperplasia by progesterone during long-term estradiol replacement: influence of bleeding pattern and secretory changes. Fertil Steril 1993;59:992–7
- Archer DF, Dorin M, Lewis V, Schneider DL, . Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on endometrial bleeding. Fertil Steril 2001;75:1080–7
- Jacobs I, Gentry-Maharaj A, Burnell M, . Sensitivity of transvaginal ultrasound screening for endometrial cancer in postmenopausal women: a case-control study within the UKCTOCS cohort. Lancet Oncol 2011;12:38–48
- Cano A. Compliance to hormone replacement therapy in menopausal women controlled in a third level academic centre. Maturitas 1994;20:91–9
- Hulley S, Grady D, Bush T, . Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605–13
- Nelson H. Commonly used types of postmenopausal estrogens for treatment of hot flashes. JAMA 2004;291:1610–20